ThinkEquity Initiates Coverage on Gen-Probe (GPRO) with a Buy
GPRO Hot Sheet
Rating Summary:4 Buy, 15 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
ThinkEquity initiates coverage on Gen-Probe (Nasdaq: GPRO) with a Buy rating. Price target $55.
To see more analyst ratings on GRPO Click Here.
Gen-Probe Incorporated (Gen-Probe) is engaged in the development, manufacture and marketing of nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood.
To see more analyst ratings on GRPO Click Here.
Gen-Probe Incorporated (Gen-Probe) is engaged in the development, manufacture and marketing of nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood.
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Nomura Securities Maintains a 'Neutral' on Tiffany & Co. (TIF); Cutting Estimates and Price Target
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
Create E-mail Alert Related Categories
New CoverageRelated Entities
ThinkEquitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
